Ipravent (Ipratropium Bromide)

Ipratropium bromide blocks muscarinic (M3) receptors on airway smooth muscle, preventing acetylcholine‑induced contraction. This antagonism stops bronchoconstriction, allowing the bronchi to remain relaxed and the airway diameter to increase, which facilitates easier breathing.

The prescribed dose of Ipravent is determined by the treating physician based on the patient’s condition, severity and response to therapy. Dosing regimens may vary, and the prescriber will provide specific instructions for each individual.

Safety data for ipratropium bromide in pregnancy and lactation are limited. Healthcare providers should weigh potential benefits against possible risks and discuss any concerns with the patient before prescribing Ipravent to pregnant or nursing women.

To request Ipravent, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ipravent (ipratropium) is an anticholinergic bronchodilator that works by blocking muscarinic receptors, whereas albuterol is a short‑acting β2‑agonist that stimulates smooth‑muscle relaxation. Ipratropium has a slower onset but a longer duration and is often used in combination with β2‑agonists for additive bronchodilation in COPD and asthma.

Ipravent should be stored at room temperature, below 25 °C, in its original container. Protect the product from moisture and direct sunlight. Do not freeze the inhalation solution, and keep it out of reach of children.

Ipravent is delivered via a metered‑dose inhaler or nebulizer as directed by a healthcare professional. The patient inhales the prescribed number of puffs or nebulized doses, typically using a spacer or mouthpiece to ensure optimal lung deposition.

Serious adverse reactions, though rare, include paradoxical bronchospasm, severe allergic responses such as angioedema, and significant airway irritation that may worsen breathing. Patients should seek immediate medical attention if they experience sudden worsening of respiratory symptoms or signs of an allergic reaction.

Ipravent is contraindicated in patients with a known hypersensitivity to ipratropium bromide or any component of the formulation. Caution is advised for individuals with narrow‑angle glaucoma, urinary retention, or severe renal impairment, and it should be avoided in those with a history of severe allergic reactions to anticholinergic agents.